Vulvovaginal candidiasis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Vulvovaginal candidiasis - Pipeline Insight, 2021,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Vulvovaginal candidiasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Vulvovaginal candidiasis: Overview
Vulvovaginal candidiasis (VVC) is a local yeast infection typically caused by Candida albicans. Non?albicans species have also been associated with VVC, including C. glabrata, C. tropicalis, and C. parapsilosis. Non?albicans infections are thought to be more resistant to topical imidazole and triazole therapies. Patients with VVC typically present with vulvar or vaginal pruritus and burning, with or without dysuria. A thick white floccular discharge (like cottage cheese) is often noted. Vulvovaginal candidiasis is due to an overgrowth of yeasts within the vagina, most often C. albicans. About 20% of non-pregnant women aged 15–55 harbour C. albicans in the vagina without any symptoms.
'Vulvovaginal candidiasis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vulvovaginal candidiasis pipeline landscape is provided which includes the disease overview and Vulvovaginal candidiasis treatment guidelines. The assessment part of the report embraces, in depth Vulvovaginal candidiasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vulvovaginal candidiasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Vulvovaginal candidiasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vulvovaginal candidiasis Emerging Drugs
Further product details are provided in the report..
Vulvovaginal candidiasis: Therapeutic Assessment
This segment of the report provides insights about the different Vulvovaginal candidiasis drugs segregated based on following parameters that define the scope of the report, such as:
Vulvovaginal candidiasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vulvovaginal candidiasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vulvovaginal candidiasis drugs.
Vulvovaginal candidiasis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Vulvovaginal candidiasis - Pipeline Insight, 2021,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Vulvovaginal candidiasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Vulvovaginal candidiasis: Overview
Vulvovaginal candidiasis (VVC) is a local yeast infection typically caused by Candida albicans. Non?albicans species have also been associated with VVC, including C. glabrata, C. tropicalis, and C. parapsilosis. Non?albicans infections are thought to be more resistant to topical imidazole and triazole therapies. Patients with VVC typically present with vulvar or vaginal pruritus and burning, with or without dysuria. A thick white floccular discharge (like cottage cheese) is often noted. Vulvovaginal candidiasis is due to an overgrowth of yeasts within the vagina, most often C. albicans. About 20% of non-pregnant women aged 15–55 harbour C. albicans in the vagina without any symptoms.
'Vulvovaginal candidiasis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vulvovaginal candidiasis pipeline landscape is provided which includes the disease overview and Vulvovaginal candidiasis treatment guidelines. The assessment part of the report embraces, in depth Vulvovaginal candidiasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vulvovaginal candidiasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Vulvovaginal candidiasis R&D. The therapies under development are focused on novel approaches to treat/improve Vulvovaginal candidiasis.
This segment of the Vulvovaginal candidiasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vulvovaginal candidiasis Emerging Drugs
- Oteseconazole: Mycovia Pharmaceuticals
- MAT2203: Matinas BioPharma
Further product details are provided in the report..
Vulvovaginal candidiasis: Therapeutic Assessment
This segment of the report provides insights about the different Vulvovaginal candidiasis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Vulvovaginal candidiasis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intraveous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Antifungals
- Polymer
- Small molecule
- Gene therapy
- Product Type
Vulvovaginal candidiasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vulvovaginal candidiasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vulvovaginal candidiasis drugs.
Vulvovaginal candidiasis Report Insights
- Vulvovaginal candidiasis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Vulvovaginal candidiasis drugs?
- How many Vulvovaginal candidiasis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vulvovaginal candidiasis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vulvovaginal candidiasis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vulvovaginal candidiasis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Mycovia Pharmaceuticals
- Matinas BioPharma
- NovaDigm Therapeutics
- Toltec Pharmaceuticals
- LTN Pharm
- ProFem
- Ferrer
- Mariposa Health
- Oteseconazole
- MAT2203
- NDV 3
- TOL 463
- Myc 102
- ProF 001
- Arasertaconazole
- M-010
Introduction
Executive Summary
Vulvovaginal candidiasis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vulvovaginal candidiasis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vulvovaginal candidiasis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vulvovaginal candidiasis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Oteseconazole: Mycovia Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Arasertaconazole: Ferrer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Vulvovaginal candidiasis Key Companies
Vulvovaginal candidiasis Key Products
Vulvovaginal candidiasis- Unmet Needs
Vulvovaginal candidiasis- Market Drivers and Barriers
Vulvovaginal candidiasis- Future Perspectives and Conclusion
Vulvovaginal candidiasis Analyst Views
Vulvovaginal candidiasis Key Companies
Appendix
Executive Summary
Vulvovaginal candidiasis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vulvovaginal candidiasis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vulvovaginal candidiasis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vulvovaginal candidiasis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Oteseconazole: Mycovia Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Arasertaconazole: Ferrer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Vulvovaginal candidiasis Key Companies
Vulvovaginal candidiasis Key Products
Vulvovaginal candidiasis- Unmet Needs
Vulvovaginal candidiasis- Market Drivers and Barriers
Vulvovaginal candidiasis- Future Perspectives and Conclusion
Vulvovaginal candidiasis Analyst Views
Vulvovaginal candidiasis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Vulvovaginal candidiasis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Vulvovaginal candidiasis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Vulvovaginal candidiasis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Vulvovaginal candidiasis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
